Search
Dehydrocholic acid
go.drugbank.com/drugs/DB11622ApprovedThe use of dehydrocholic acid in over-the-counter products has been discontinued by Health Canada.
Products: Dycholium Tablet 300mgAmfecloral
go.drugbank.com/drugs/DB08924Experimentalin its own right. … This would produce an effect similar to the amphetamine/barbiturate combinations previously used in psychiatric medications.
Rabeximod
go.drugbank.com/drugs/DB05772InvestigationalRabeximod is an orally administered compound for treatment of moderate or severe active rheumatoid arthritis that is currently undergoing phase II clinical testing in eight European countries.
Sphingosine
go.drugbank.com/drugs/DB03203InvestigationalAn amino alcohol with a long unsaturated hydrocarbon chain. Sphingosine and its derivative sphinganine are the major bases of the sphingolipids in mammals. (Dorland, 28th ed)
Lunacalcipol
go.drugbank.com/drugs/DB05024Investigationalsecretion which may be involved in the etiology of psoriasis. … Preclinical studies have shown that CTA018 inhibits the proliferation of rapidly dividing cells such as human epidermal keratinocytes (skin cells) and is also effective in inhibiting pro-inflammatory cytokine
Morrhuic acid
go.drugbank.com/drugs/DB14087InvestigationalMorrhuic acid is a mixture of unsaturated fatty acids obtained from cod liver oil.
Categories: Compounds used in a research, industrial, or household settingCEP-1347
go.drugbank.com/drugs/DB05403InvestigationalCEP-1347 is a semi-synthetic compound shown to protect multiple nerve cell types from a variety of insults leading to programmed cell death (apoptosis) which could improve the survival of dopamine neurons prior to and after transplantation.
Chlorocresol
go.drugbank.com/drugs/DB16864InvestigationalCategories: Compounds used in a research, industrial, or household settingGoralatide
go.drugbank.com/drugs/DB20748ExperimentalGoralatide is a small molecule drug. Goralatide has a monoisotopic molecular weight of 487.23 Da.
Categories: Compounds used in a research, industrial, or household settingOdanacatib
go.drugbank.com/drugs/DB06670InvestigationalOdanacatib is an inhibiter of cathepsin K which was originally developed be Merck & Co as a new treatment for osteoporosis [A19388].